AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38225561 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening the mind - a work-focused intervention combining the capability approach and the participatory approach in one-on-one coaching by trained work coaches who have MS themselves
Number of subjects: 270
Study 38225561 — intervention group
Group type: COMPARATOR
Intervention: Control group - receiving general information about cognitive impairment in MS and receiving care as usual
Number of subjects: 270
Study 38225579 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 17.5 mg weekly by subcutaneous injection for 12 months
Number of subjects: 40
Study 38225579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 38225579 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 40
Study 38225589 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin, sulfasalazine, memantine and chemoradiotherapy (Arm A)
Number of subjects: 120
Study 38225589 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy alone (Arm B)
Number of subjects: 120
Study 38225598 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose oral favipiravir (3.6g on day 0 followed by 1.6g daily for 7 days)
Number of subjects: 240
Study 38225598 — intervention group
Group type: COMPARATOR
Intervention: No study drug (Control)
Number of subjects: 240
Study 38225633 — intervention group
Group type: EXPERIMENTAL
Intervention: Task shifting for TCD screening
Number of subjects: 7
Study 38225633 — intervention group
Group type: EXPERIMENTAL
Intervention: Task shifting
Number of subjects: 7
Study 38225650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential levofloxacin-based treatment regimen
Number of subjects: 300
Study 38225650 — intervention group
Group type: COMPARATOR
Intervention: Concomitant levofloxacin-based regimen
Number of subjects: 300
Study 38225650 — intervention group
Group type: COMPARATOR
Intervention: High-dose dual therapy (proton-pump inhibitor and amoxicillin)
Number of subjects: 300
Study 38225677 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted TranS-C
Number of subjects: 154
Study 38225677 — intervention group
Group type: COMPARATOR
Intervention: Standard TranS-C
Number of subjects: 154
Study 38225677 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider perceptions of fit
Number of subjects: 154
Study 38225952 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IR HDM SLIT tablet
Number of subjects: 818
Study 38225952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study 38225983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoperfusion-hypodensity mismatch
Number of subjects: 247
Study 38225983 — intervention group
Group type: COMPARATOR
Intervention: Automated perfusion mismatch
Number of subjects: 247
Study 38226285 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO)
Number of subjects: 8
Study 38226445 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal HIV-test-and-treat intervention
Number of subjects: 90801
Study 38226445 — intervention group
Group type: COMPARATOR
Intervention: Control (population-level HIV testing at baseline and endline)
Number of subjects: 90801
Study 38226491 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-tiered intervention involving training in palliative care and a new consultation model, with medical consultations every 3 weeks for 12 weeks.
Number of subjects: 53
Study 38226507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application with just-in-time adaptive intervention promoting physical activity and lower-sodium food choices, including weekly goal setting.
Number of subjects: 484
Study 38226507 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 484
Study 38226507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application notifications.
Number of subjects: 484
Study 38226511 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrie Hybrid CR program combined with usual care CR
Number of subjects: 200
Study 38226511 — intervention group
Group type: COMPARATOR
Intervention: Usual care CR alone
Number of subjects: 200
Study 38226512 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message-based mHealth intervention
Number of subjects: 17
Study 38226931 — intervention group
Group type: EXPERIMENTAL
Intervention: N-803 plus BCG therapy
Number of subjects: 164
Study 38227007 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-back task
Number of subjects: 60
Study 38227007 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-back task
Number of subjects: 60
Study 38227007 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal fluency test (VFT)
Number of subjects: 60
Study 38227032 — intervention group
Group type: EXPERIMENTAL
Intervention: Default palliative care consultation
Number of subjects: 24065
Study 38227032 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24065
Study 38227033 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab + chemotherapy
Number of subjects: 501
Study 38227033 — intervention group
Group type: COMPARATOR
Intervention: Placebo + chemotherapy
Number of subjects: 501
Study 38227034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse and social worker palliative telecare team (6 phone calls with a nurse for symptom management and 6 phone calls with a social worker for psychosocial care).
Number of subjects: 306
Study 38227034 — intervention group
Group type: COMPARATOR
Intervention: Usual care (educational handout for self-care).
Number of subjects: 306
Study 38227034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse and social worker palliative telecare team.
Number of subjects: 306
Study 38227308 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiStem (1.2 billion cells, intravenous)
Number of subjects: 206
Study 38227308 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous)
Number of subjects: 206
Study 38227315 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy-informed discharge medication communication bundle (n=99)
Number of subjects: 198
Study 38227315 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling (n=99)
Number of subjects: 198
Study 38227355 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaverse group (exercise video distribution in metaverse space)
Number of subjects: 48
Study 38227355 — intervention group
Group type: EXPERIMENTAL
Intervention: YouTube group (exercise video distribution via YouTube)
Number of subjects: 48
Study 38227355 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special instructions)
Number of subjects: 48
Study 38227362 — intervention group
Group type: EXPERIMENTAL
Intervention: iDBT (immediate access group)
Number of subjects: 72
Study 38227362 — intervention group
Group type: EXPERIMENTAL
Intervention: iDBT (both groups)
Number of subjects: 72
Study 38227362 — intervention group
Group type: COMPARATOR
Intervention: iDBT (delayed access group)
Number of subjects: 72
Study 38227447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification of antihypertensive therapy with maximally tolerated doses of a β-blocker, a long-acting dihydropyridine calcium channel blocker, and a renin-angiotensin system inhibitor.
Number of subjects: 0
Study 38227447 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and dialysate restricted in sodium to facilitate achievement of dry weight.
Number of subjects: 0
Study 38227447 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate time on dialysis of at least 4 hours for delivering an adequate dialysis dose.
Number of subjects: 0
Study 38227538 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided focused ultrasound thalamotomy
Number of subjects: 10
Study 38227621 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg/d
Number of subjects: 60
Study 38227621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 38227687 — intervention group
Group type: EXPERIMENTAL
Intervention: Summed stress score
Number of subjects: 400
Study 38227687 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperemic myocardial blood flow (MBF)
Number of subjects: 400
Study 38227697 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus narrowing via reducer implantation
Number of subjects: 24
Study 38227830 — intervention group
Group type: EXPERIMENTAL
Intervention: N2-N3 sleep EEG power in delta (0.5-4 Hz)
Number of subjects: 127
Study 38227830 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow delta power (0.5-1 Hz)
Number of subjects: 127
Study 38227830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast delta power (1-4 Hz)
Number of subjects: 127
Study 38227830 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta power (all frequency bands)
Number of subjects: 127
Study 38227898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab
Number of subjects: 0
Study 38227898 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study 38227933 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A (4000 IU/kg, maximum 250,000 IU)
Number of subjects: 80
Study 38227933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 38227934 — intervention group
Group type: EXPERIMENTAL
Intervention: ANA-associated AIC with ANA titer ≥1/160
Number of subjects: 1803
Study 38227934 — intervention group
Group type: EXPERIMENTAL
Intervention: ANA-associated AIC with ANA titer >1/160
Number of subjects: 1803
Study 38227934 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >10 years at AIC diagnosis
Number of subjects: 1803
Study 38227934 — intervention group
Group type: COMPARATOR
Intervention: ANA-negative test
Number of subjects: 1803
Study 38227934 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe manifestations of SLE
Number of subjects: 1803
Study 38227963 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 450
Study 38227963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 38228054 — intervention group
Group type: EXPERIMENTAL
Intervention: 5C participants
Number of subjects: 115
Study 38228054 — intervention group
Group type: COMPARATOR
Intervention: OACC patients
Number of subjects: 115
Study 38228287 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (onabotA)
Number of subjects: 75
Study 38228287 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 75
Study 38228387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined standard medical treatment (SMT) and endovascular thrombectomy (EVT)
Number of subjects: 221
Study 38228467 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a familial hypercholesterolemia (FH) screening program in primary care.
Number of subjects: 0
Study 38228467 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to FH screening implementation.
Number of subjects: 0
Study 38228467 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators for FH screening implementation.
Number of subjects: 0
Study 38228467 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined implementation strategy package for FH screening.
Number of subjects: 0
Study 38229072 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein dose
Number of subjects: 1277
Study 38229112 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal titin fragment measurement
Number of subjects: 0
Study 38229112 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine kinase (CK) measurement
Number of subjects: 0
Study 38229143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-modal 12-week hatha yoga program (2 60-min group classes a week)
Number of subjects: 0
Study 38229181 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic sleep treatment (six sessions)
Number of subjects: 88
Study 38229181 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education (single session)
Number of subjects: 88
Study 38229197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 6
Study 38229197 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (HCD)
Number of subjects: 6
Study 38229197 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (HD)
Number of subjects: 6
Study 38229199 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg octreotide subcutaneous depot (CAM2029) every 2 weeks (Q2W)
Number of subjects: 300
Study 38229199 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice of SRL therapy at standard doses (octreotide LAR 30 mg or lanreotide ATG 120 mg every 4 weeks [Q4W])
Number of subjects: 300
Study 38229269 — intervention group
Group type: EXPERIMENTAL
Intervention: Damoctocog alfa pegol (BAY 94-9027, Jivi) at 45 IU/kg every 5 days or 40 IU/kg twice-weekly
Number of subjects: 36
Study 38229269 — intervention group
Group type: EXPERIMENTAL
Intervention: Damoctocog alfa pegol (BAY 94-9027, Jivi)
Number of subjects: 36
Study 38229349 — intervention group
Group type: EXPERIMENTAL
Intervention: Attainment of lupus low disease activity state (LLDAS) at any timepoint
Number of subjects: 1707
Study 38229349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative time in LLDAS
Number of subjects: 1707
Study 38229349 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased durations of sustained LLDAS
Number of subjects: 1707
Study 38229356 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib monotherapy (masked methotrexate withdrawal)
Number of subjects: 533
Study 38229356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib plus methotrexate
Number of subjects: 533
Study 38229357 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI303 (40 mg subcutaneous injection every 2 weeks)
Number of subjects: 438
Study 38229357 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (40 mg subcutaneous injection every 2 weeks)
Number of subjects: 438
Study 38229357 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI303 (per-protocol population)
Number of subjects: 438
Study 38229357 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (per-protocol population)
Number of subjects: 438
Study 38229357 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI303
Number of subjects: 438
Study 38229357 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 438
Study 38229377 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 457
Study 38229377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 38229392 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment with three Lactobacillus strains (Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus plantarum DSM 15313; 1 x 10^9 CFU)
Number of subjects: 249
Study 38229392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 38229519 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial Measurement Units during the 6-Minute Walking Test (6MWT)
Number of subjects: 72
Study 38229914 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled anesthetics after total intravenous anesthesia (TIVA)
Number of subjects: 1
Study 38229914 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 1
Study 38230727 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive games or Web-based crossword puzzles
Number of subjects: 105
Study 38230727 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT cohort (Computerized Cognitive Training)
Number of subjects: 105
Study 38230875 — intervention group
Group type: EXPERIMENTAL
Intervention: Costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI)
Number of subjects: 25
Study 38230875 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 25
Study 38230875 — intervention group
Group type: EXPERIMENTAL
Intervention: CCP-ACI
Number of subjects: 25
Study 38231017 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PDN) 1 mg/kg per day from days 0 to 28 (Arm A)
Number of subjects: 113
Study 38231017 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HD-DXM) 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B)
Number of subjects: 113
Study 38231017 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PDN)
Number of subjects: 113
Study 38231017 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HD-DXM)
Number of subjects: 113
Study 38231017 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 113
Study 38231017 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall disease-free survival
Number of subjects: 113
Study 38231079 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg daily for 14 days) plus standard of care
Number of subjects: 66
Study 38231079 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 66
Study 38231126 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Number of subjects: 302
Study 38231126 — intervention group
Group type: COMPARATOR
Intervention: TC (treatment choice)
Number of subjects: 302
Study 38231282 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pneumoperitoneum (Pnp) of 7 mmHg
Number of subjects: 98
Study 38231282 — intervention group
Group type: COMPARATOR
Intervention: Standard pneumoperitoneum (Pnp) of 12 mmHg
Number of subjects: 98
Study 38231282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Low Pnp and Standard Pnp)
Number of subjects: 98
Study 38231313 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE intervention
Number of subjects: 100
Study 38231361 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention (long-term child development account, micro-enterprise workshops, educational sessions)
Number of subjects: 455
Study 38231361 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 455
Study 38231380 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic intervention programme
Number of subjects: 60
Study 38231380 — intervention group
Group type: COMPARATOR
Intervention: Human-instructed programme
Number of subjects: 60
Study 38231380 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 38231502 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port robotic nipple-sparing mastectomy (SPrNSM)
Number of subjects: 20
Study 38231511 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Psychotherapy (BA)
Number of subjects: 416
Study 38231511 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant Medication Management (MEDS)
Number of subjects: 416
Study 38231536 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week blended intervention combining weekly face-to-face group sessions and a digital companion app
Number of subjects: 16
Study 38231552 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBT (n=301)
Number of subjects: 603
Study 38231552 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBT plus OHC (n=302)
Number of subjects: 603
Study 38231552 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=101)
Number of subjects: 603
Study 38231552 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBT
Number of subjects: 603
Study 38231552 — intervention group
Group type: EXPERIMENTAL
Intervention: OHC
Number of subjects: 603
Study 38231570 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention, trialed 1 to 2 weeks preoperatively, average engagement time 12 minutes.
Number of subjects: 7
Study 38231570 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual).
Number of subjects: 7
Study 38231576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 1341
Study 38231576 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKA)
Number of subjects: 1341
Study 38231588 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal central sensitization (CS) induction protocol
Number of subjects: 66
Study 38231588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptive withdrawal reflex magnitude (NWR-M)
Number of subjects: 66
Study 38231588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptive withdrawal reflex response rate (NWR-RR) at the rectus femoris
Number of subjects: 66
Study 38231588 — intervention group
Group type: COMPARATOR
Intervention: Sham protocol
Number of subjects: 66
Study 38231590 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary CD4 + T-cell counts
Number of subjects: 102
Study 38231590 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of urinary CD4 + T-cell counts with proteinase-3 ANCA levels
Number of subjects: 102
Study 38231621 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel applied daily
Number of subjects: 5204
Study 38231621 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel applied daily
Number of subjects: 5204
Study 38231623 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg per kilogram of body weight)
Number of subjects: 32877
Study 38231623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32877
Study 38231622 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT defibrillator (CRT-D)
Number of subjects: 1050
Study 38231622 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillators (ICD)
Number of subjects: 1050
Study 38231624 — intervention group
Group type: EXPERIMENTAL
Intervention: Simnotrelvir plus ritonavir (750 mg of simnotrelvir plus 100 mg of ritonavir, twice daily for 5 days)
Number of subjects: 1208
Study 38231624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1208
Study 38231624 — intervention group
Group type: EXPERIMENTAL
Intervention: Simnotrelvir plus ritonavir
Number of subjects: 1208
Study 38231777 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 17
Study 38232095 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA score
Number of subjects: 2851
Study 38232095 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS criteria
Number of subjects: 2851
Study 38232095 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS/NEWS2/MEWS
Number of subjects: 2851
Study 38232100 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle education intervention (six weeks of fortnightly six sessions, 45 minutes per session)
Number of subjects: 250